COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,646 Articles (22,913 medRxiv, 8,733 bioRxiv)

Most recent first Previous |  Page 1432: Articles 14311-14320  | Next

What We Learned From COVID 19? Trying to find best approach from pathophysiology to treatment.
Dirican, A., Ildir, S., Uzar, T., Karaman, I., OZKAYA, S.
10.1101/2021.07.05.21259790 — Posted: 2021-07-07
Peritraumatic Distress of COVID-19 on Physicians in Bangladesh: Implications and Policy Recommendations
Ahmad, Z., Kium, A. a., Ahammed, M. R., Hamid, M. M., Tarannum, S., Amin, M. R., Islam, M. D.
10.1101/2021.07.05.21250138 — Posted: 2021-07-07
Modelling, Simulations and Analysis of the First and Second COVID-19 Epidemics in Beijing
Min, L.
10.1101/2021.07.04.21259205 — Posted: 2021-07-07
Excess years of life lost to COVID-19 and other causes of death by sex, neighbourhood deprivation and region in England & Wales during 2020
Kontopantelis, E., Mamas, M. A., Webb, R. T., Castro-Avila, A., Rutter, M. K., Gale, C. P., Ashcroft, D. M., Pierce, M., Abel, K. M., Price, G., Faivre-Finn, C., Van Spall, H. G. C., Graham, M. M., Morciano, M., Martin, G. P., Sutton, M., Doran, T.
10.1101/2021.07.05.21259786 — Posted: 2021-07-07
Incidence of Severe Acute Respiratory Syndrome Coronavirus-2 infection among previously infected or vaccinated employees
Kojima, N., Roshani, A., Brobeck, M., Baca, A., Klausner, J. D.
10.1101/2021.07.03.21259976 — Posted: 2021-07-07 Discussion: Onsite
Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19
Barouch, D. H., Stephenson, K., Sadoff, J., Yu, J., Chang, A., Gebre, M., McMahan, K., Liu, J., Chandrashekar, A., Patel, S., Le Gars, M., de Groot, A., Heerwegh, D., Struyf, F., Douoguih, M., van Hoof, J., Schuitemaker, H.
10.1101/2021.07.05.21259918 — Posted: 2021-07-07 Discussion: Onsite
Critical Role of the Subways in the Initial Spread of SARS-CoV-2 in New York City
Harris, J. E.
10.1101/2021.07.03.21259973 — Posted: 2021-07-07
Anaesthetic Higher Specialty Training Recruitment in the United Kingdom During the COVID-19 Pandemic: A National Survey
Durrant, F., Edwardson, S., El-Ghazali, S., Holt, C., McCrossan, R., Pramanik, I., Subramaniam, J., Wong, D. J. N.
10.1101/2021.07.03.21259616 — Posted: 2021-07-07 Discussion: Onsite
SARS-CoV-2 IgG detection in human oral fluids
Hoschler, K., Ijaz, S., Andrews, N., Ho, S., Dicks, S., Jegatheesan, K., Poh, J., Warrener, L., Kankeyan, T., Baawuah, F., Beckmann, J., Okike, I. O., Ahmad, S., Garstang, J., Brent, A. J., Brent, B., Aiano, F., Brown, K. E., Ramsay, M. E., Brown, D. W., Parry, J. V., Ladhani, S. N., Zambon, M.
10.1101/2021.07.07.21260121 — Posted: 2021-07-07
Anticoagulants and Antiplatelets in COVID-19: Impact on Survival and Thromboembolism Development
Salmon, T., Titley, M., Noori, Z., Crosby, M., Sankaranarayanan, R.
10.1101/2021.07.03.21254541 — Posted: 2021-07-07

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).